Table 2.

Clinical characteristics of ITP patients receiving decitabine treatment

PatientsAge, ySexPlatelet count, ×109/LAntiplatelet antibodiesMajor previous drugs
Anti-GPIIb/IIIaAnti-GPIb/IX
21 − − DXM, Pred, rhTPO, TPO-RA 
46 19 − DXM, rhTPO, CA, 
51 25 − − DXM, Pred, 
60 − DXM, Pred, RTX, SP 
26 13 − − DXM, IVIG, rhTPO 
70 14 − − DXM, Pred, IVIG, rhTPO 
34 DXM, Pred, RTX 
42 28 − − DXM, rhTPO 
31 11 − − DXM, Pred, CA 
10 65 20 − DXM, Pred, rhTPO, Danazol 
11 48 12 − − DXM, rhTPO, CA 
12 18 14 − − Pred, rhTPO, CsA 
13 45 16 − − DXM, IVIG, RTX 
PatientsAge, ySexPlatelet count, ×109/LAntiplatelet antibodiesMajor previous drugs
Anti-GPIIb/IIIaAnti-GPIb/IX
21 − − DXM, Pred, rhTPO, TPO-RA 
46 19 − DXM, rhTPO, CA, 
51 25 − − DXM, Pred, 
60 − DXM, Pred, RTX, SP 
26 13 − − DXM, IVIG, rhTPO 
70 14 − − DXM, Pred, IVIG, rhTPO 
34 DXM, Pred, RTX 
42 28 − − DXM, rhTPO 
31 11 − − DXM, Pred, CA 
10 65 20 − DXM, Pred, rhTPO, Danazol 
11 48 12 − − DXM, rhTPO, CA 
12 18 14 − − Pred, rhTPO, CsA 
13 45 16 − − DXM, IVIG, RTX 

CA, caffeic acid; CsA, cyclosporine A; IVIg, intravenous gamma globulin; Pred, prednisone; rhTPO, recombinant human thrombopoietin; RTX, rituximab; SP, splenectomy, danazol; TPO-RA, thrombopoietin receptor agonist.

or Create an Account

Close Modal
Close Modal